Fear is a major factor behind people’s reluctance to take part in clinical research, such as trials to test new medicines and treatments, a global review has found.
In the UK, up to two thirds of trials currently fail to recruit their target number of participants for vital medical research.
The review, led by researchers at the University of York and Hull York Medical School, found that fear about testing new treatments and possible side effects was the most common reason given by patients for not wanting to participate.
Thanks for this 2g. A while ago I took part in a Delphi - three rounds. The participants were made up of 2 thirds clinicians and 1 third people with bronchiectasis. We all seemed to be on the same page (or should I say tick boxes) until it came to side effects. That’s where differences of opinions appeared. Quite a few thought side effects were ‘of little importance’. So I appreciate some folks reluctance and the odd rogue ‘of little importance’ regarding death from any cause or death from bronch or an infirmity was an eye opener.
Hat’s off to anyone who has and does take part in trials.
I concur with you cofdrop, and support trials and the volunteers who sign up for them.
I’m always looking for trials to take part in. I did a year-long stage III trial about 8 years ago & it was extremely useful. Unfortunately I couldn’t stay on the drug long term as it eventually caused bronchospasm, but it’s now helping people with cystic fibrosis.
I remember that Hanne and what a bummer you couldn’t stay on it. As I recall it was quite promising for you initially. It must be rewarding though to know you have helped our cf brothers and sisters.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Aspergillus post lung transplant.
My results and treatment plan after my Cystoscopy OP.
After seeing new Consultant last week
New drug approved in Europe for uncontrolled COPD. 
institual lung disease
